Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
This study aims to collect prospective safety and effectiveness data for the C-Brace System, a microprocessor-controlled knee ankle foot orthosis, following standard care practices. The research focuses on patients with lower extremity pareses who are fitted with the C-Brace device. The goal is to better understand how the C-Brace influences walking speed, balance, risk of falling, and confidence in balance over time. The C-Brace is a custom-made device with thigh, calf, and foot components connected by an ankle joint or spring element. It uses sensors to continuously monitor knee joint movement and walking phases, adjusting hydraulic resistance and knee motion accordingly. Patients enrolled in the registry will undergo baseline evaluation, fitting, training or therapy sessions, and follow-up visits at 6, 12, 24, and 36 months after fitting. Participants will be assessed through various tests including timed walk tests, balance confidence scores, and mobility assessments at different intervals. The study also tracks falls related to device use and changes in activity levels with an activity tracker. Data collected will help characterize the safety and functional impact of the C-Brace over three years of follow-up.
Actively Recruiting
Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.
Actively Recruiting
Researchers are studying the effects of lunsekimig, given as a subcutaneous injection, in adults aged 40 to 80 years with chronic obstructive pulmonary disease COPD that is not well controlled and characterized by an eosinophilic phenotype. This Phase 2bPhase 3, randomized, double-blind, placebo-controlled study compares two dosing regimens of lunsekimig against placebo to evaluate its efficacy, safety, and tolerability over a prolonged period. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a matching placebo. They will receive subcutaneous injections during a treatment period of about 48 weeks. The study includes a screening phase lasting up to 4 weeks before treatment, followed by an 8-week follow-up after the intervention, totaling up to 60 weeks of participation. During the trial, participants will undergo regular assessments including lung function tests, symptom questionnaires like the Chronic Airways Assessment Test CAAT, and monitoring of exacerbations and adverse events. Researchers will measure the rate of moderate to severe COPD exacerbations as the primary outcome. Safety labs, antibody testing, and drug concentration monitoring will also occur. Participants will be monitored throughout the study duration, including follow-up after treatment ends.
Actively Recruiting
Researchers are evaluating treatments for men with metastatic prostate cancer, a condition where cancer has spread beyond the prostate to other parts of the body. This phase III trial compares standard systemic therapy alone versus standard systemic therapy combined with definitive treatment of the primary tumor, such as prostate removal surgery or radiation therapy. The goal is to see if adding these local treatments improves survival and delays cancer progression. Participants begin with an induction period of 22 to 28 weeks receiving one of six forms of standard systemic therapy, which may include hormone therapies like goserelin or leuprolide injections, oral medications such as abiraterone or bicalutamide, or chemotherapy with docetaxel. After induction, participants are randomly assigned to continue systemic therapy alone or to receive systemic therapy plus prostatectomy within 8 weeks or radiation therapy within 4 weeks. The study includes tissue and blood sample collection for future research. Throughout the trial, participants have regular assessments including physical exams, laboratory tests measuring PSA and testosterone levels, and imaging scans to monitor disease status. Patient-reported quality of life related to urinary function, pain, and physical abilities is also evaluated over several years. After treatment, participants are followed for up to eight years to track overall survival, progression-free survival, and local symptom progression, providing a comprehensive understanding of treatment effects over time.
Actively Recruiting
Researchers are evaluating the addition of stereotactic body radiation therapy SBRT to the usual treatment for patients with locally advanced, inoperable non-small cell lung cancer that has spread to nearby tissue or lymph nodes. This phase III trial compares the effect of SBRT combined with conventional image guided radiation therapy IGRT, chemotherapy, and subsequent immunotherapy or targeted therapy to the usual treatment alone. The goal is to see if adding SBRT improves overall survival and progression-free survival. Participants are randomly assigned to one of two groups. Arm I receives conventional IGRT with chemotherapy regimens including paclitaxel, carboplatin, pemetrexed, cisplatin, or etoposide during radiotherapy, followed by consolidation immunotherapy with durvalumab or targeted therapy with osimertinib. Arm II receives SBRT to the primary tumor plus conventional IGRT to nodal metastases along with the same chemotherapy and consolidation treatments. Imaging with CT or PETCT scans is used during follow-up. During the study, participants undergo regular assessments including scans and pulmonary function tests at baseline and at 6 and 12 months after radiation therapy. Researchers also collect patient-reported outcomes and monitor quality of life, adverse events, and changes in lung function over time. Biospecimens and advanced imaging data are collected for further analysis. Participants are followed every 3 months for the first year, then every 6 months for years 2 and 3, and yearly thereafter, for up to 13 years total.